Phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior therapies.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rachel N. Grisham, Dilip D. Giri, Alexia Iasonos, Qin Zhou, Jeffrey Girshman, Sean Patrick McGrath, Oana-Paula Orodel, Roisin Eilish O'Cearbhaill, Nancy E. Mills, Tiffany A. Troso-Sandoval, Paul Sabbatini, William P. Tew, David Michael Hyman, Martee Leigh Hensley, Dmitriy Zamarin, Jason A. Konner, Alexandra Snyder Charen, Karen Anne Cadoo, Gopa Iyer, Carol Aghajanian
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891199468